|
|
Volumn 24, Issue 2, 2001, Pages 104-105
|
|
Issues on Clinical Applications of Cancer Vaccines
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
ADVANCED CANCER;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL;
DOSE CALCULATION;
DOSE RESPONSE;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
LIFE EXPECTANCY;
MAXIMUM PERMISSIBLE DOSE;
NOTE;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SERODIAGNOSIS;
T LYMPHOCYTE ACTIVATION;
VACCINATION;
ADENOCARCINOMA;
CA-15-3 ANTIGEN;
CANCER VACCINES;
CLINICAL TRIALS, PHASE I;
HUMANS;
IMMUNOTHERAPY, ACTIVE;
NEOPLASMS;
T-LYMPHOCYTES;
|
|
EID: 0035123686
PISSN: 15249557
EISSN: 15374513
Source Type: Journal
DOI: 10.1097/00002371-200103000-00003 Document Type: Editorial |
|
Times cited : (7)
|
|
References (0)
|
